Loading company
Loading
Latest annual · FY2025
Millions- Free cash flow
- (154)
Latest quarter · Q3 FY2026
Millions- Operating income
- (43)
- Net income
- (42)
Kyverna Therapeutics, Inc. (KYTX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$169.8 million | -$142.6 million | 10-K 2026-03-26 · proof | |
| Net income | -$161.3 million | -$127.5 million | 10-K 2026-03-26 · proof | |
| Cash from operating activities | -$153.7 million | -$114.3 million | 10-K 2026-03-26 · proof | |
| Free cash flow | -$153.7 million | -$116.5 million | 10-K 2026-03-26 · proof | |
| Total assets | $293.8 million | $304.6 million | -3.6% | 10-K 2026-03-26 · proof |
| Total liabilities | $61.6 million | $38.1 million | +61.7% | 10-K 2026-03-26 · proof |
| Cash and cash equivalents | $124.1 million | $96.6 million | +28.4% | 10-K 2026-03-26 · proof |
- What was Kyverna Therapeutics, Inc. (KYTX)'s operating income in fiscal 2025?
- Kyverna Therapeutics, Inc. (KYTX) reported operating income of -$169.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$142.6 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Kyverna Therapeutics, Inc. (KYTX)'s net income in fiscal 2025?
- Kyverna Therapeutics, Inc. (KYTX) reported net income of -$161.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$127.5 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Kyverna Therapeutics, Inc. (KYTX)'s cash from operating activities in fiscal 2025?
- Kyverna Therapeutics, Inc. (KYTX) reported cash from operating activities of -$153.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$114.3 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was Kyverna Therapeutics, Inc. (KYTX)'s free cash flow in fiscal 2025?
- Kyverna Therapeutics, Inc. (KYTX) reported free cash flow of -$153.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$116.5 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are Kyverna Therapeutics, Inc. (KYTX)'s total assets?
- As of Dec 31, 2025, Kyverna Therapeutics, Inc. (KYTX) reported total assets of $293.8 million, against $304.6 million a year earlier (-3.6%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are Kyverna Therapeutics, Inc. (KYTX)'s total liabilities?
- As of Dec 31, 2025, Kyverna Therapeutics, Inc. (KYTX) reported total liabilities of $61.6 million, against $38.1 million a year earlier (+61.7%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are Kyverna Therapeutics, Inc. (KYTX)'s cash and cash equivalents?
- As of Dec 31, 2025, Kyverna Therapeutics, Inc. (KYTX) reported cash and cash equivalents of $124.1 million, against $96.6 million a year earlier (+28.4%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:KYTX&period_type=annual&limit=5"Information only, not investment advice.